Radiation Oncologist, Associate Professor @ Yonsei Cancer Center, Seoul, Korea (Breast/Oligometastases/SABR)
Nov 4, 2025 • 6 tweets • 3 min read
1/
Our new editorial asks whether MDT for OMD has been too often treated as a one-time upfront intervention.
Have we overlooked the value of a comprehensive, longitudinal strategy—combining close surveillance with serial, strategic SABR when needed?
👉 doi.org/10.1016/j.canl…2/
In SABR-COMET, re-tx w/ SABR occurred only in the MDT arm, but later trials—where clinical equipoise faded—showed frequent crossovers.
Re-tx rates reached 26% (up to 50%) in MDT arms and 36.5% (up to 78%) in controls.
This approach resembles how brain mets are managed.
